Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years o

Trial Details

NCT ID
NCT07476287
Phase
PHASE2
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • PF-08634404
  • Chemotherapy
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Hinsdale, Illinois, United States|41.80086,-87.93701
  • New Lenox, Illinois, United States|41.51198,-87.96561
  • Porto Alegre, Brazil|-30.03283,-51.23019

Key Eligibility Criteria

  • Male or female participants aged ≥18 years at the time of informed consent.
  • Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC…
  • Participants have not received systemic therapy for T-SCLC.
  • Have at least one measurable lesion as the target lesion based on RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →